Literature DB >> 37879

Regression of left ventricular hypertrophy during treatment with antihypertensive agents.

L S Hill, M Monaghan, P J Richardson.   

Abstract

1 Echocardiography showed 14 of 24 patients with essential hypertension to have hypertrophy of their left ventricular walls. In eight of these 14 patients the left ventricular configuration initially fulfilled the criteria for asymmetric septal hypertrophy (ASH) and six were symmetrically hypertrophied, the remaining ten being normal. 2 Following 12 weeks' treatment of hypertension with the object of reducing the supine BP to 150/90 mmHg or below, there was a reduction of wall thickness so that only two of the eight continued to show ASH. 3 The six patients with symmetrical left ventricular hypertrophy also showed a significant reduction in the thickness of the septum and the posterior wall. Those with normal echocardiograms did not change. 4 This reduction of wall thickness produced by antihypertensive therapy may represent regression of left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37879      PMCID: PMC1429326          DOI: 10.1111/j.1365-2125.1979.tb04698.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Study of left ventricular wall thickness and dimension changes using echocardiography.

Authors:  T A Traill; D G Gibson; D J Brown
Journal:  Br Heart J       Date:  1978-02

2.  Measurement of left ventricular wall thickness and mass by echocardiography.

Authors:  B L Troy; J Pombo; C E Rackley
Journal:  Circulation       Date:  1972-03       Impact factor: 29.690

3.  Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis.

Authors:  C E Clark; W L Henry; S E Epstein
Journal:  N Engl J Med       Date:  1973-10-04       Impact factor: 91.245

4.  Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS.

Authors:  W L Henry; C E Clark; S E Epstein
Journal:  Circulation       Date:  1973-02       Impact factor: 29.690

5.  Hypertension and muscular subaortic stenosis.

Authors:  E Moreyra; P Knibbe; A N Brest
Journal:  Chest       Date:  1970-01       Impact factor: 9.410

6.  Hypertension and hypertrophic subaortic stenosis.

Authors:  R I Hamby; G S Roberts; J M Meron
Journal:  Am J Med       Date:  1971-10       Impact factor: 4.965

7.  Echocardiographic classification of hypertensive heart disease. A correlative study with clinical features.

Authors:  H Toshima; Y Koga; H Yoshioka; T Akiyoshi; N Kimura
Journal:  Jpn Heart J       Date:  1975-07

8.  Left ventricular performance in patients with left ventricular hypertrophy caused by systemic arterial hypertension.

Authors:  J S Karlinger; D Williams; J Gorwit; M H Crawford; R A O'Rourke
Journal:  Br Heart J       Date:  1977-11

9.  Cardiac hypertrophy and antihypertensive therapy.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Cardiovasc Res       Date:  1977-09       Impact factor: 10.787

10.  Coronary heart-disease after treatment of hypertension.

Authors:  G Berglund; R Sannerstedt; O Andersson; H Wedel; L Wilhelmsen; L Hansson; R Sivertsson; J Wikstrand
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

  10 in total
  12 in total

1.  Early regression of left ventricular diastolic abnormalities in hypertensive patients treated with nifedipine.

Authors:  I Sheiban; G Covi; C Zenorini; G Arcaro; E Arosio; S Tonni; G Montresor; A Lechi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Comparison between the effects of urapidil and methyldopa on left ventricular hypertrophy and haemodynamics in humans.

Authors:  C A Feldstein; A O Olivieri; R P Sabarís
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Treatment of essential hypertension: changes in blood pressure, echocardiography and electrocardiography on three therapeutic regimes.

Authors:  G I Russell; J E Pohl; J Baldwin; R F Bing; A M Heagerty; H Thurston; J D Swales
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Control of blood pressure and reduction of echocardiographically assessed left ventricular mass with one-daily timolol.

Authors:  D B Rowlands; D R Glover; T J Stallard; W A Littler
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

5.  Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine.

Authors:  L A Ferrara; G de Simone; M Mancini; M L Fasano; F Pasanisi; G Vallone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Regression of left ventricular hypertrophy on long-term treatment with captopril of severe hypertensives refractory to standard triple treatment.

Authors:  U de Faire; K Lindvall; G Andersson; S Eriksson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.

Authors:  W Linz; J Schaper; G Wiemer; U Albus; B A Schölkens
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

8.  Relationship between hypertension and angina pectoris.

Authors:  P J Richardson; L S Hill
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 9.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 10.  Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.